Apligraf

About Organogenesis

Organogenesis's mission is to empower healing by delivering regenerative tissue innovations. The company has achieved significant milestones, including receiving one of the first FDA approvals for a living, human-cell-based product (Apligraf®) and building a leading portfolio of commercial products for advanced wound care and surgical biologics. Its strategy focuses on leveraging its foundational 3D cell delivery platform, expanding manufacturing capacity, and supporting patients through comprehensive access programs to drive growth in the regenerative medicine market.

Therapeutic Areas